Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade
- 551 Downloads
The novel antidepressant agent, agomelatine, behaves as an agonist at melatonin receptors and as an antagonist at serotonin (5-HT)2C receptors.
To determine whether, by virtue of its antagonist properties at 5-HT2C receptors, agomelatine elicits anxiolytic properties in rats.
Employing a combined neurochemical and behavioural approach, actions of agomelatine were compared to those of melatonin, the selective 5-HT2C receptor antagonist, SB243,213, and the benzodiazepine, clorazepate.
In unfamiliar pairs of rats exposed to a novel environment, agomelatine enhanced the time devoted to active social interaction, an action mimicked by clorazepate and by SB243,213. In a Vogel conflict procedure, agomelatine likewise displayed dose-dependent anxiolytic activity with a maximal effect comparable to clorazepate, and SB243,213 was similarly active in this procedure. In a plus-maze procedure in which clorazepate significantly enhanced percentage entries into open arms, agomelatine revealed only modest activity and SB243,213 was inactive. Further, like SB243,213, and in contrast to clorazepate, agomelatine did not suppress ultrasonic vocalizations emitted by rats re-exposed to an environment associated with an aversive stimulus. Whereas clorazepate reduced dialysate levels of 5-HT and noradrenaline in hippocampus and frontal cortex of freely moving rats, agomelatine did not affect extracellular levels of 5-HT and elevated those of noradrenaline. SB243,213 acted similarly to agomelatine. Melatonin, which did not modify extracellular levels of 5-HT or noradrenaline, was ineffective in all models of anxiolytic activity. Furthermore, the selective melatonin antagonist, S22153, did not modify anxiolytic properties of agomelatine in either the social interaction or the Vogel Conflict tests.
In contrast to melatonin, and reflecting blockade of 5-HT2C receptors, agomelatine is active in several models of anxiolytic properties in rodents. The anxiolytic profile of agomelatine differs from that of benzodiazepines from which it may also be distinguished by its contrasting influence on corticolimbic monoaminergic pathways.
KeywordsMelatonin 5-HT2C receptors Anxiety Anxiolytic Conflict Frontal cortex Dorsal hippocampus
The authors thank Laetitia Cistarelli, Brigitte Denorme, Huguette Gressier, Loretta Iob, Rodolphe Billiras, Christophe Melon and Jimmy Mullot for technical assistance, and Marianne Soubeyran for secretarial assistance. E. Mocäer is thanked for helpful comments on the manuscript.
- Cardinali DP, Gvozdenovich E, Kaplan MR, Fainstein I, Shifis HA, Pérez Lloret S, Albornoz L, Negri A (2002) A double blind-placebo controlled study on melatonin efficacy to reduce anxiolytic benzodiazepine use in the elderly. Neuroendocrinol Lett 23:55–60Google Scholar
- Chagraoui A, Protais P, Filloux T, Mocaër E (2003) Agomelatine (S20098) antagonizes the penile erections induced by the stimulation of 5-HT2C receptors in Wistar rats. Psychopharmacology 170:17–22Google Scholar
- Das S, Tecott L (1996) Diminished anxiety-like responses in 5-HT2C receptor mutant mice. Soc Neurosci Abstr 22:811–812Google Scholar
- Deakin JFW (1994) Three distinct roles of 5-HT in anxiety, panic and depression. In: Montgomery SA, Corn TH (eds) Psychopharmacology of depression. British Association for Psychopharmacology, Cambridge, vol 13, pp 87–101Google Scholar
- Dekeyne A, Brocco M, Adhumeau A, Gobert A, Millan MJ (2000a) The selective serotonin 5-HT1A receptor ligand, S15535, displays anxiolytic-like effects in the social interaction and Vogel models and suppresses dialysate levels of 5-HT in the dorsal hippocampus of freely-moving rats: a comparison with other anxiolytic agents. Psychopharmacology 152:55–66Google Scholar
- Foote SL, Aston-Jones GS (1995) Pharmacology and physiology of central noradrenergic systems. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation in progress. Raven, New York, pp 347–354Google Scholar
- Gobert A, Rivet J-M, Lejeune F, Newman-Tancredi A, Adhumeau-Auclair A, Nicolas J-P, Cistarelli L, Melon C, Millan MJ (2000) Serotonin2C receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat. Synapse 36:205–221CrossRefPubMedGoogle Scholar
- Jenck F, Bös M, Wichmann J, Stadler H, Martin JR, Moreau JL (1998) The role of 5-HT2C receptors in affective disorders. Exp Opin Invest Drugs 7:1587–1599Google Scholar
- Kleven MS, Koek W (1999) Effects of benzodiazepine agonists on punished responding in pigeons and their relationship with clinical doses in humans. Psychopharmacology 141:206–212Google Scholar
- Krueger KE (1991) Peripheral-type benzodiazepine receptors: a second site of action for benzodiazepines. Neuropharmacology 4:237–244Google Scholar
- Lôo H, D’haenen H, Hale A (2002a) A double-blind study of S20098 in patients with major depressive or bipolar II disorders: effect on anxiety. Int J Neuropsychopharmacol 5:P3.E.031Google Scholar
- Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, Dekeyne A, Nicolas JP, Lejeune F (2000a) Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of α2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci 12:1079–1095CrossRefPubMedGoogle Scholar
- Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V, Rivet J-M, Cussac D (2003) The novel melatonin agonist, agomelatine (S20098), is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 306:954–964CrossRefPubMedGoogle Scholar
- Van Reeth O, Weibel L, Olivares E, Maccari S, Mocaër E, Turek FW (2001) Melatonin or a melatonin agonist correct age-related changes in circadian response to an environmental stimulus. Am J Physiol 280:1582–1591Google Scholar
- Wiley JL, Dance ME, Balster BL (1998) Preclinical evaluation of the reinforcing and discriminative stimulus effects of agomelatine (S20098), a melatonin agonist. Psychopharmacology 140:503–509Google Scholar
- Wood MD, Reavill C, Trail B, Wilson A, Stean T, Kennett GA, Lightowler S, Blackburn TP, Thomas D, Gager TL, Riley G, Holland V, Bromidge SM, Forbes IT, Middlemiss DN (2001) SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety. Neuropharmacology 41:186–199CrossRefPubMedGoogle Scholar
- Yoshioka K, Xie F, Gitzen JF, Kissinger CB, Kissinger PT (2000) Preliminary study of the effects of melatonin administration on the release of endogenous 5-HT and its metabolite in rat SCN. Curr Separation 18:117–122Google Scholar